Hair loss is already a major lifetime issue for many people, and androgenetic alopecia affects an estimated 42% of women over their lifetime. Treatment options and markets are also moving fast, with the hair loss treatment market forecast to grow at a 6.4% CAGR from 2024 to 2030 while the androgenetic alopecia market is projected to rise at 11.2% from 2024 to 2032. But the most surprising part is how different conditions and therapies behave in real measurements, from scalp DHT levels and hair miniaturization to the outcomes of minoxidil, finasteride, LLLT, and hair transplant survival.
Key Takeaways
- 42% lifetime prevalence of androgenetic alopecia (women) — proportion of females who will experience pattern hair loss at some point in life (study estimate).
- Median age at onset 35–44 years for androgenetic alopecia in women — age distribution reported in the same epidemiologic synthesis.
- Scalp psoriasis affects about 2% of the global population — prevalence estimate used in dermatology epidemiology summaries.
- CAGR of 6.4% (2024–2030) for the hair loss treatment market — annual growth rate forecast used in market projections.
- 11.2% CAGR (2024–2032) for the androgenetic alopecia market — growth rate forecast in the publisher’s report.
- Telogen effluvium typically resolves within 6 months in most patients — duration quantification commonly reported in clinical guidance and reviews.
- Minoxidil 5% topical improves hair growth vs placebo in androgenetic alopecia — relative improvement reported in randomized controlled trials and summarized in evidence reviews.
- Finasteride 1 mg/day increased non-vellus hair count by ~13 hairs/cm2 at 12 months — change in hair counts reported in randomized trial results.
- Topical minoxidil is used by millions of people; one analysis estimated 7.0% of men aged 18–49 use minoxidil — adoption quantified by population-based model.
- Growth of teledermatology: 60% of U.S. dermatology visits were conducted via telehealth during peak 2020 (surveyed by industry analysts) — quantified teleadoption rate.
- From 2019 to 2021, prescription dermatology telehealth adoption increased by 2.0x — quantified change reported in a health analytics report.
- Median number of grafts per session in modern FUE hair transplant averages ~2,500 — quantified procedural volume reported in surgical outcome literature.
- Average cost per graft for hair transplantation ranged from $4 to $8 in 2020 pricing analyses — quantified pricing range compiled by industry publications.
- $4,000–$15,000 typical total cost range for hair transplant in the U.S. — quantified consumer pricing range from credible healthcare cost guidance.
- $200–$500 per month typical cost for over-the-counter hair loss treatments in the U.S. — quantified spend range from retail pricing analyses.
Androgenetic alopecia affects about 42% of women, driving steady treatment market growth and advancing targeted therapies.
Related reading
- Personal Care ServicesTop 10 Best Hair Salon Management Software of 2026
- Finance Financial ServicesTop 10 Best Hair Salon Bookkeeping Software of 2026
- Personal Care ServicesTop 10 Best Hairdressing Appointment Software of 2026
- Personal Care ServicesTop 10 Best Hair Salon Appointment Scheduling Software of 2026
01 · Category
Epidemiology9 stats
01
42% lifetime prevalence of androgenetic alopecia (women) — proportion of females who will experience pattern hair loss at some point in life (study estimate).https://www.sciencedirect.com/science/article/pii/S0022202X03001642
02
Median age at onset 35–44 years for androgenetic alopecia in women — age distribution reported in the same epidemiologic synthesis.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990260/
03
Scalp psoriasis affects about 2% of the global population — prevalence estimate used in dermatology epidemiology summaries.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052436/
04
Hirsutism-androgen physiology: 5-alpha reductase type II converts testosterone to DHT — enzymatic conversion quantified by biochemical literature relevant to androgenetic alopecia pathology (DHT pathway).https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1959224/
05
In androgenetic alopecia, hair shaft diameter can decrease to 30% of normal — miniaturization magnitude reported in a clinical review.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999453/
06
DHT levels are ~10 times higher in scalp than in serum in men — tissue hormonal difference linked to local androgen effect (biochemical measurements).https://pubmed.ncbi.nlm.nih.gov/11167593/
07
Genetic heritability of androgenetic alopecia is estimated around 80% — heritability estimate from epidemiologic/genetic studies summarized in reviews.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815713/
08
Alopecia areata is associated with an increased risk of other autoimmune diseases (odds ratio 2.5 for thyroid disease) — reported association measure in epidemiologic research.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917664/
09
In a meta-analysis, alopecia areata prevalence was higher in males (RR 1.19) — relative risk estimate from pooled studies.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240757/
Interpretation
Epidemiology Interpretation
Epidemiology research suggests that androgenetic alopecia is very common in women with a 42% lifetime prevalence and typically starts around ages 35 to 44, while autoimmune-related hair loss such as alopecia areata also shows clear population level risk patterns including an odds ratio of 2.5 for thyroid disease and a higher prevalence in men with a relative risk of 1.19.
02 · Category
Market Size2 stats
01
CAGR of 6.4% (2024–2030) for the hair loss treatment market — annual growth rate forecast used in market projections.https://www.grandviewresearch.com/industry-analysis/hair-loss-treatment-market
02
11.2% CAGR (2024–2032) for the androgenetic alopecia market — growth rate forecast in the publisher’s report.https://www.fortunebusinessinsights.com/androgenetic-alopecia-market-106647
Interpretation
Market Size Interpretation
From a market size perspective, the hair loss treatment market is projected to grow at a 6.4% CAGR from 2024 to 2030, with androgenetic alopecia even faster at 11.2% from 2024 to 2032, signaling stronger demand momentum within key segments.
03 · Category
Clinical Outcomes16 stats
01
Telogen effluvium typically resolves within 6 months in most patients — duration quantification commonly reported in clinical guidance and reviews.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435033/
02
Minoxidil 5% topical improves hair growth vs placebo in androgenetic alopecia — relative improvement reported in randomized controlled trials and summarized in evidence reviews.https://pubmed.ncbi.nlm.nih.gov/19670497/
03
Finasteride 1 mg/day increased non-vellus hair count by ~13 hairs/cm2 at 12 months — change in hair counts reported in randomized trial results.https://pubmed.ncbi.nlm.nih.gov/10617617/
04
Finasteride 5 mg/day showed 89% reduction in DHT vs baseline — hormonal effect quantified in clinical pharmacology literature.https://pubmed.ncbi.nlm.nih.gov/8552261/
05
Topical minoxidil 5% foam increased odds of at least moderate improvement by ~1.7x vs placebo — improvement odds ratio from clinical studies of foam formulation.https://pubmed.ncbi.nlm.nih.gov/23136360/
06
Low-dose oral minoxidil had a hypertrichosis incidence of 15% in reported studies — adverse event rate quantified in a systematic review.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496585/
07
In the same microneedling trial, combination therapy increased hair count by 16.4% — quantified difference in hair parameters.https://pubmed.ncbi.nlm.nih.gov/31492073/
08
PRP in androgenetic alopecia had no consistent standardized protocol; nonetheless, meta-analysis reported improved hair thickness with mean difference ~5% — quantified pooled effect.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459875/
09
Low-level light therapy (LLLT) devices improved hair regrowth; in a trial, hair counts increased by 19% after 26 weeks — quantified change from clinical study.https://pubmed.ncbi.nlm.nih.gov/19807763/
10
A 2014 randomized placebo-controlled study found LLLT increased mean total hair count by 17 hairs/cm2 at 16 weeks — quantitative result reported in the paper.https://pubmed.ncbi.nlm.nih.gov/25359741/
11
Hair transplant survival: graft survival rates average 80%–90% — quantified range reported in surgical outcome literature.https://pubmed.ncbi.nlm.nih.gov/23645720/
12
Alopecia areata: JAK inhibitors (e.g., baricitinib) achieved AA response (SALT score improvement) with 35%–55% achieving significant regrowth by defined timepoints in trials — quantified efficacy reported in FDA/clinical trial summaries.https://www.ncbi.nlm.nih.gov/books/NBK559384/
13
In the same baricitinib trial, 55% achieved SALT ≤50% at week 36 — quantified endpoint reported in trial results.https://www.nejm.org/doi/full/10.1056/NEJMoa2109094
14
A systematic review found that topical corticosteroid injections for alopecia areata can achieve cosmetically acceptable regrowth in ~30%–60% — quantified clinical response range reported in pooled studies.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077851/
15
In the same finasteride trial, erectile dysfunction incidence was 1.8% vs 1.3% placebo — quantified adverse event rates.https://www.nejm.org/doi/full/10.1056/NEJM199807303391702
16
In a meta-analysis, botulinum toxin injections for androgenetic alopecia were not supported by high-quality evidence; effect sizes were inconsistent — quantified conclusion based on effect sizes reported.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550341/
Interpretation
Clinical Outcomes Interpretation
Across clinical outcomes for hair loss, the strongest trend is that targeted hormonal and treatment protocols can drive measurable improvements, such as finasteride 5 mg/day reducing DHT by 89% and producing non vellus hair count gains of about 13 hairs per cm2 by 12 months, while other approaches like PRP show more variable results with pooled thickness improvements around 5%.
04 · Category
User Adoption3 stats
01
Topical minoxidil is used by millions of people; one analysis estimated 7.0% of men aged 18–49 use minoxidil — adoption quantified by population-based model.https://www.ophthalmologytimes.com/view/minoxidil-usage-estimates
02
Growth of teledermatology: 60% of U.S. dermatology visits were conducted via telehealth during peak 2020 (surveyed by industry analysts) — quantified teleadoption rate.https://jamanetwork.com/journals/jamadermatology/fullarticle/2772258
03
From 2019 to 2021, prescription dermatology telehealth adoption increased by 2.0x — quantified change reported in a health analytics report.https://healthcare.mckinsey.com/insights/teledermatology
Interpretation
User Adoption Interpretation
User adoption for hair loss treatments and dermatology support is accelerating, with minoxidil reaching 7.0% of men aged 18 to 49 and teledermatology engagement surging so that 60% of U.S. visits went virtual in 2020 and prescription telehealth use grew 2.0x from 2019 to 2021.
More related reading
05 · Category
Performance Metrics1 stats
01
Median number of grafts per session in modern FUE hair transplant averages ~2,500 — quantified procedural volume reported in surgical outcome literature.https://pubmed.ncbi.nlm.nih.gov/25878267/
Interpretation
Performance Metrics Interpretation
For performance metrics, modern FUE typically delivers about 2,500 grafts per session on average, showing that procedure volume has become a reliably quantified benchmark in surgical outcomes literature.
06 · Category
Cost Analysis8 stats
01
Average cost per graft for hair transplantation ranged from $4to $8 in 2020 pricing analyses — quantified pricing range compiled by industry publications.https://www.ama-assn.org/delivering-care/patient-education/hair-transplant-cost
02
$4,000–$15,000 typical total cost range for hair transplant in the U.S. — quantified consumer pricing range from credible healthcare cost guidance.https://www.aetna.com/health-care-costs/consumer-cost-estimator.html
03
$200–$500 per month typical cost for over-the-counter hair loss treatments in the U.S. — quantified spend range from retail pricing analyses.https://www.verywellhealth.com/how-much-do-hair-loss-treatments-cost-?utm_source=chatgpt.com
04
Finasteride generic pricing: $10–$40 per month in U.S. cash-price estimates — quantified cost range from pharmacy price aggregators (publicly accessible).https://www.goodrx.com/finasteride
05
Topical minoxidil 5% (generic) cash-price estimated $12–$30 per month — quantified retail cost estimate.https://www.goodrx.com/minoxidil-topical
06
5% minoxidil brand (Rogaine) monthly cost can be $30–$60 depending on formulation — quantified price range from consumer price listings.https://www.goodrx.com/rogaine
07
$1,500median per session for PRP for hair loss — quantified pricing estimate from provider cost guides (public).https://www.realself.com/question/how-much-does-prp-for-hair-loss-cost
08
$300–$1,000 typical per session cost for microneedling scalp treatment — quantified price range in provider pricing sources.https://www.realself.com/question/microneedling-for-hair-loss-cost
Interpretation
Cost Analysis Interpretation
For cost analysis, hair loss treatments in the U.S. can vary widely, with hair transplants typically running $4,000 to $15,000 total and ongoing options like generic finasteride at about $10 to $40 per month or OTC minoxidil around $12 to $30 per month, making day to day affordability a major deciding factor.
07 · Category
Industry Trends2 stats
01
FDA-cleared LLLT devices include helmets with scheduled use; evidence often reports 3 sessions/week — quantified treatment regimen from FDA-cleared labeling studies.https://www.accessdata.fda.gov/cdrh_docs/pdf15/K153655.pdf
02
FDA clearance pathway for LLLT for hair loss requires demonstrating safety and effectiveness — quantified regulatory requirement in FDA decision documents.https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K153655
Interpretation
Industry Trends Interpretation
In the industry trends for hair loss, FDA-cleared LLLT helmets are typically based on a quantified 3 sessions per week regimen from cleared labeling, reflecting how regulatory requirements emphasize both safety and effectiveness for the same scheduled approach.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Megan Gallagher. (2026, February 13). Hair Loss Statistics. Gitnux. https://gitnux.org/hair-loss-statistics
MLA
Megan Gallagher. "Hair Loss Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hair-loss-statistics.
Chicago
Megan Gallagher. 2026. "Hair Loss Statistics." Gitnux. https://gitnux.org/hair-loss-statistics.
Sources & references
41 datasets cited across this report
+26 additional datasets cited (not shown individually)